
12/09/2024
Atomo Diagnostics is pleased to advise that its partner Lumos Diagnostics has recently commenced a capital raising initiative to secure up to A$10 million, noting that the raise is underwritten by institutional investors for up to A$6 million.
Stated use of funds includes a clinical trial to support CLIA Waiver of FebriDx™ in the US market. FebriDx™ utilises Atomo’s Pascal cassette and its integrated usability to support performance in decentralised settings covered by CLIA Waiver.
CLIA Waiver of a rapid test significantly increases the addressable market in the US. With Pascal's user-centric design and leading performance in the hands of lay users, CLIA Waiver would provide a pathway for other rapid test assays for the US market.
Atomo continues to engage with potential partners with respect to opportunities for the US market, with a funded pathway to a CLIA waived Pascal based test being helpful in further de-risking this process.
To learn more about Atomo's Pascal platform, click the link below
https://bit.ly/3Ts7FZp